The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this report, we present a comprehensive market forecast for the current and emerging chimeric antigen receptor (CAR) T-cell therapies across oncology indications. We also provide key opinion leaders’(KOLs’) insights regarding the current and emerging CAR T-cell treatment landscape.


  • What is the commercial potential of CAR T-cell therapies by brand, indication, and geography?
  • How will the CAR T-cell market evolve over the 2017-2027 forecast period?
  • What are the ongoing clinical trials of currently approved CAR T-cell therapies? Which additional indications and settings do we expect Kymriah and Yescarta to secure?
  • Which emerging CAR T-cell therapies do we anticipate will gain approval, and will they be commercially successful?
  • What are the strengths and weaknesses of each brand, and what are KOLs’ opinions of each therapy?
  • What challenges could limit the adoption of autologous CD19-targeted CAR T-cell therapies? What are the competitive threats and pressures thatCAR T-celltherapiesareexpected to face in the oncology landscape?
  • What are the opinions of expert oncologists on the future CAR T-cell therapy landscape?

United States, EU5, Japan

14 country-specific interviews with thought-leading hematologist-oncologists and trial investigators.

Drug-treated patient populations for acute lymphoblastic leukemia, relevant non-Hodgkin’s lymphoma subpopulations, chronic lymphocytic leukemia, and multiple myeloma, by country and line of therapy.

Ten-year, annualized, drug-level sales and patient shares for CAR T-cell therapies through 2027, segmented by indication and patient subpopulation.

The CAR T-Cell Therapy Special Topics Report is a unique product offering a consolidated full market forecast of the CAR T-cell landscape in oncology through 2027. This forecast is supplemented with interviews conducted with KOLs from all seven major pharmaceutical markets under study.

Table of contents

  • Chimeric Antigen Receptor (CAR) T-Cell Therapy - Landscape & Forecast - Special Topics: CAR T-Cell Therapy Forecast - Multi-indication
    • Special Topics CAR T-Cell Therapies US, EU5, Japan March 2019

Author(s): Andrew Merron, PhD

Andrew Merron, Ph.D., is the Therapy Lead for oncology and biosimilars at Decision Resources. In this capacity he is responsible for the team delivering high quality, timely, and relevant insights and forecasts. In addition, Dr. Merron drives the strategic direction of the team, builds and maintains long-term strategic partnerships with clients, and translates domain knowledge into substantial value for the department.

Previously, Dr. Merron managed the Biosimilars Advisory Service across therapy areas, and prior to this he was a principal analyst in the oncology group. He has extensive experience in forecasting oncology and hematology-oncology drug markets as well as considerable experience in conducting primary research with physicians and payers. Prior to joining Decision Resources, Dr. Merron received his Ph.D. in molecular oncology from the University of London. His doctorate focused on molecular imaging of cancer immunotherapies, specifically therapeutic oncolytic adenoviruses.